Federated Hermes’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-85
Closed -$1.14K 2188
2023
Q4
$1.14K Sell
85
-3
-3% -$38 ﹤0.01% 1970
2023
Q3
$1.08K Sell
88
-2
-2% -$24 ﹤0.01% 2005
2023
Q2
$1.11K Hold
90
﹤0.01% 2024
2023
Q1
$1.11K Hold
90
﹤0.01% 2041
2022
Q4
$1.03K Sell
90
-1
-1% -$8 ﹤0.01% 2053
2022
Q3
$1K Hold
91
﹤0.01% 2130
2022
Q2
$1K Hold
91
﹤0.01% 2125
2022
Q1
$1K Hold
91
﹤0.01% 2165
2021
Q4
$1K Sell
91
-129
-59% -$560 ﹤0.01% 2193
2021
Q3
$1K Hold
220
﹤0.01% 2195
2021
Q2
$1K Sell
220
-2
-0.9% -$13 ﹤0.01% 2186
2021
Q1
$1K Hold
222
﹤0.01% 2206
2020
Q4
$2K Sell
222
-111
-33% -$547 ﹤0.01% 2150
2020
Q3
$1K Sell
333
-59
-15% -$217 ﹤0.01% 2237
2020
Q2
$1K Sell
392
-635
-62% -$2.17K ﹤0.01% 2222
2020
Q1
$2K Sell
1,027
-805
-44% -$2.35K ﹤0.01% 2059
2019
Q4
$6K Hold
1,832
﹤0.01% 1953
2019
Q3
$8K Sell
1,832
-1,545
-46% -$7.72K ﹤0.01% 1915
2019
Q2
$16K Sell
3,377
-7,443
-69% -$35.3K ﹤0.01% 1841
2019
Q1
$59K Sell
10,820
-50,599
-82% -$233K ﹤0.01% 1640
2018
Q4
$187K Sell
61,419
-488
-0.8% -$1.69K ﹤0.01% 1564
2018
Q3
$260K Sell
61,907
-51,898
-46% -$219K ﹤0.01% 1571
2018
Q2
$440K Sell
113,805
-24,962
-18% -$166K ﹤0.01% 1434
2018
Q1
$879K Sell
138,767
-10,842
-7% -$89.7K ﹤0.01% 1268
2017
Q4
$1.21M Buy
+149,609
New +$1.39M ﹤0.01% 1154
2016
Q4
Sell
-12,710
Closed -$635K 2235
2016
Q3
$635K Buy
12,710
+2,542
+25% +$106K ﹤0.01% 1217
2016
Q2
$431K Hold
10,168
﹤0.01% 1317
2016
Q1
$670K Sell
10,168
-835
-8% -$43.6K ﹤0.01% 1200
2015
Q4
$684K Buy
11,003
+3,377
+44% +$238K ﹤0.01% 1203
2015
Q3
$511K Sell
7,626
-11,740
-61% -$958K ﹤0.01% 1278
2015
Q2
$1.88M Buy
19,366
+11,308
+140% +$1.08M 0.01% 943
2015
Q1
$753K Buy
8,058
+2,974
+58% +$253K ﹤0.01% 1261
2014
Q4
$452K Sell
5,084
-5,084
-50% -$370K ﹤0.01% 1374
2014
Q3
$702K Hold
10,168
﹤0.01% 1274
2014
Q2
$583K Buy
+10,168
New +$516K ﹤0.01% 1317

Other funds holding MACK

Federated Hermes's MACK Position: Q1 2024 in Review

Federated Hermes sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2024, closing a stake of 85 shares — an estimated $1.14K sold.

Federated Hermes first reported a position in MACK in Q2 2014 and held it in 35 quarters. The position peaked at $1.88M in Q2 2015. 70 funds tracked by Wall St. Rank hold MACK as of Q1 2024.

  • Federated Hermes reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Federated Hermes sold 85 Merrimack Pharmaceuticals, Inc. shares in Q1 2024, an estimated $1.14K.
  • Federated Hermes first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 35 quarters.
  • Federated Hermes's Merrimack Pharmaceuticals, Inc. position peaked at $1.88M in Q2 2015.
  • 70 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2024.

Based on Federated Hermes's 13F filing for Q1 2024, filed 14 May 2024.